The world's first oral GLP-1RA Novoxin (semaglutide tablets) is fully launched in China

2025-01-11 18:48:09

Novo Nordisk announced that the world's first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) - Novoxin (semaglutide tablets) has been fully launched in China. With its convenient oral administration method, Novoxin helps patients benefit from GLP-1RA drugs earlier, helps achieve high-quality blood sugar targets and comprehensive metabolic management, and brings an innovative category to the clinical treatment of type 2 diabetes in China.

Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Oppenheimer: Raises Nvidia (NVDA.O) price target from $175 to $200.
                            2025-07-15

                                    Shanghai: Accelerate the implementation of major engineering projects and build core capabilities of the smart glasses industry
                            2025-07-15

                                    ETF Midday Review: ChiNext Artificial Intelligence ETF Southern led the gains by 4.95%, while the CSI 2000 ETF Fund led the losses by 4.36%
                            2025-07-15

                                    Tesla Model Y long-range rear-wheel drive version is priced at about RMB 567,000 in India
                            2025-07-15

                                    BOE A: Will submit a review to the ITC regarding the preliminary ruling of the 337 investigation on trade secrets
                            2025-07-15